共 39 条
[1]
Torre LA(2017)Global cancer in women: burden and trends Cancer Epidemiol Biomarkers Prev 26 444-457
[2]
Islami F(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30
[3]
Siegel RL(2014)US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status J Natl Cancer Inst 34 3069-3103
[4]
Siegel RL(2016)Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline J Clin Oncol 11 R77-35
[5]
Miller KD(2009)PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro Breast Cancer Res 16 25-1936
[6]
Jemal A(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 375 1925-439
[7]
Howlader N(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 17 425-1547
[8]
Altekruse SF(2016)Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Lancet Oncol 29 1541-3646
[9]
Li CI(2018)Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Ann Oncol 35 3638-2472
[10]
Rugo HS(2017)MONARCH 3: abemaciclib as initial therapy for advanced breast cancer J Clin Oncol 20 37-1936